[1]
|
Mahmood, S.S., Patel, R.B., Butler, J., et al. (2018) Epirubicin and Long-Term Heart Failure Risk in Breast Cancer Sur-vivors. European Journal of Heart Failure, 20, 1454-1456. https://doi.org/10.1002/ejhf.1215
|
[2]
|
Ameri, P., Canepa, M., Anker, M.S., et al. (2018) Cancer Diagnosis in Patients with Heart Failure: Epidemiology, Clinical Implica-tions and Gaps in Knowledge. European Journal of Heart Failure, 20, 879-887.
https://doi.org/10.1002/ejhf.1165
|
[3]
|
Ramkumar, S., Raghunath, A. and Raghunath, S. (2016) Statin Therapy: Re-view of Safety and Potential Side Effects. Acta Cardiological Sinica, 32, 631-639.
|
[4]
|
Sexton, T., Wallace, E.L. and Smyth, S.S. (2016) Anti-Thrombotic Effects of Statins in Acute Coronary Syndromes: At the Intersection of Thrombosis, Inflammation, and Platelet-Leukocyte Interactions. Current Cardiology Reviews, 12, 324-329. https://doi.org/10.2174/1573403X12666160504100312
|
[5]
|
Dimitroulakos, J., Nohynek, D., Backway, K.L., et al. (1999) Increased Sensitivity of Acute Myeloid Leukemias to Lovastatin-Induced Apoptosis: A Potential Therapeutic Ap-proach. Blood, 93, 1308-1318.
https://doi.org/10.1182/blood.V93.4.1308.404k08_1308_1318
|
[6]
|
Dulak, J. and Jozkowicz, A. (2005) An-ti-Angiogenic and Anti-Inflammatory Effects of Statins: Relevance to Anti-Cancer Therapy. Current Cancer Drug Tar-gets, 5, 579-594. https://doi.org/10.2174/156800905774932824
|
[7]
|
Lee, S.J., Lee, I., Lee, J., et al. (2014) Statins, 3-Hydroxy-3-Methylglutaryl Coenzyme a Reductase Inhibitors, Potentiate the Anti-Angiogenic Effects of Bevacizumab by Suppressing Angiopoietin2, BiP, and Hsp90alpha in Human Colorectal Cancer. British Journal of Cancer, 111, 497-505. https://doi.org/10.1038/bjc.2014.283
|
[8]
|
Wang, J.C., Li, X.X., Sun, X., et al. (2018) Activation of AMPK by Simvastatin Inhibited Breast Tumor Angiogenesis via Impeding HIF-1alpha-Induced Pro-Angiogenic Factor. Cancer Science, 109, 1627-1637.
https://doi.org/10.1111/cas.13570
|
[9]
|
Zahedipour, F., Butler, A.E., Rizzo, M., et al. (2022) Statins and Angio-genesis in Non-Cardiovascular Diseases. Drug Discovery Today, 27, Article ID: 103320. https://doi.org/10.1016/j.drudis.2022.07.005
|
[10]
|
Mitry, M.A., Laurent, D., Keith, B.L., et al. (2020) Accelerated Cardiomyocyte Senescence Contributes to Late-Onset Doxorubicin-Induced Cardiotoxicity. American Journal of Physi-ology-Cell Physiology, 318, C380-C391.
https://doi.org/10.1152/ajpcell.00073.2019
|
[11]
|
Sobczuk, P., Czerwinska, M., Kleibert, M., et al. (2022) Anthracy-cline-Induced Cardiotoxicity and Renin-Angiotensin-Aldosterone System—From Molecular Mechanisms to Therapeutic Applications. Heart Failure Reviews, 27, 295-319. https://doi.org/10.1007/s10741-020-09977-1
|
[12]
|
Zhang, S., Liu, X., Bawa-Khalfe, T., et al. (2012) Identification of the Molecular Basis of Doxorubicin-Induced Cardiotoxicity. Na-ture Medicine, 18, 1639-1642. https://doi.org/10.1038/nm.2919
|
[13]
|
Pecoraro, M., Marzocco, S., Belvedere, R., et al. (2023) Simvastatin Reduces Doxorubicin-Induced Cardiotoxicity: Effects beyond Its Antioxidant Activity. Interna-tional Journal of Molecular Sciences, 24, Article No. 7573.
https://doi.org/10.3390/ijms24087573
|
[14]
|
Oh, J., Lee, B.S., Lim, G., et al. (2020) Atorvastatin Protects Cardio-myocyte from Doxorubicin Toxicity by Modulating Survivin Expression through FOXO1 Inhibition. Journal of Molec-ular and Cellular Cardiology, 138, 244-255.
https://doi.org/10.1016/j.yjmcc.2019.12.007
|
[15]
|
Henninger, C., Huelsenbeck, S., Wenzel, P., et al. (2015) Chronic Heart Damage Following Doxorubicin Treatment Is Alleviated by Lovastatin. Pharmacological Research, 91, 47-56. https://doi.org/10.1016/j.phrs.2014.11.003
|
[16]
|
Kim, Y.H., Park, S.M., Kim, M., et al. (2012) Cardioprotective Ef-fects of Rosuvastatin and Carvedilol on Delayed Cardiotoxicity of Doxorubicin in Rats. Toxicology Mechanisms and Methods, 22, 488-498.
https://doi.org/10.3109/15376516.2012.678406
|
[17]
|
Dadson, K., Thavendiranathan, P., Hauck, L., et al. (2022) Statins Protect against Early Stages of Doxorubicin-Induced Cardiotoxicity through the Regulation of Akt Signaling and SERCA2. CJC Open, 4, 1043-1052.
https://doi.org/10.1016/j.cjco.2022.08.006
|
[18]
|
Shahid, I., Yamani, N., Ali, A., et al. (2021) Meta-Analysis Evalu-ating the Use of Statins to Attenuate Cardiotoxicity in Cancer Patients Receiving Anthracyclines and Trastuzumab-Based Chemotherapy. American Journal of Cardiology, 156, 142-145. https://doi.org/10.1016/j.amjcard.2021.07.001
|
[19]
|
Chotenimitkhun, R., D’Agostino, R.J., Lawrence, J.A., et al. (2015) Chronic Statin Administration May Attenuate Early Anthracycline-Associated Declines in Left Ventricular Ejec-tion Function. Canadian Journal of Cardiology, 31, 302-307. https://doi.org/10.1016/j.cjca.2014.11.020
|
[20]
|
Titus, A., Cheema, H.A., Shafiee, A., et al. (2023) Statins for Attenuating Cardiotoxicity in Patients Receiving Anthracyclines: A Systematic Review and Meta-Analysis. Current Problems in Cardiology, 48, Article ID: 101885.
https://doi.org/10.1016/j.cpcardiol.2023.101885
|
[21]
|
Mohamed, A.L., El-Abd, A.A., Mohamed, H.G., et al. (2024) Role of Statin Therapy in Prevention of Anthracycline-Induced Cardiotoxicity: A Three Dimentional Echocardiography Study. Current Problems in Cardiology, 49, Article ID: 102130. https://doi.org/10.1016/j.cpcardiol.2023.102130
|
[22]
|
Neilan, T.G., Quinaglia, T., Onoue, T., et al. (2023) Atorvas-tatin for Anthracycline-Associated Cardiac Dysfunction: The STOP-CA Randomized Clinical Trial. JAMA, 330, 528-536. https://doi.org/10.1001/jama.2023.11887
|
[23]
|
De Keulenaer, G.W., Doggen, K. and Lemmens, K. (2010) The Vul-nerability of the Heart as a Pluricellular Paracrine Organ: Lessons from Unexpected Triggers of Heart Failure in Targeted ErbB2 Anticancer Therapy. Circulation Research, 106, 35-46. https://doi.org/10.1161/CIRCRESAHA.109.205906
|
[24]
|
Kabel, A.M. and Elkhoely, A.A. (2017) Targeting Proin-flammatory Cytokines, Oxidative Stress, TGF-Beta1 and STAT-3 by Rosuvastatin and Ubiquinone to Ameliorate Trastuzumab Cardiotoxicity. Biomedicine & Pharmacotherapy, 93, 17-26. https://doi.org/10.1016/j.biopha.2017.06.033
|
[25]
|
Calvillo-Arguelles, O., Abdel-Qadir, H., Michalowska, M., et al. (2019) Cardioprotective Effect of Statins in Patients with HER2-Positive Breast Cancer Receiving Trastuzumab Therapy. Canadian Journal of Cardiology, 35, 153-159.
https://doi.org/10.1016/j.cjca.2018.11.028
|
[26]
|
Abdel-Qadir, H., Bobrowski, D., Zhou, L., et al. (2021) Statin Ex-posure and Risk of Heart Failure after Anthracycline- or Trastuzumab-Based Chemotherapy for Early Breast Cancer: A Propensity Score-Matched Cohort Study. Journal of the American Heart Association, 10, E018393. https://doi.org/10.1161/JAHA.119.018393
|
[27]
|
Zamorano, J.L., Lancellotti, P., Rodriguez, M.D., et al. (2016) 2016 ESC Position Paper on Cancer Treatments and Cardiovascular Toxicity Developed Under the Auspices of the ESC Committee for Practice Guidelines: The Task Force for Cancer Treatments and Cardiovascular Toxicity of the European Society of Cardiology (ESC). European Heart Journal, 37, 2768-2801. https://doi.org/10.1093/eurheartj/ehw211
|
[28]
|
Iqubal, A., Iqubal, M.K., Sharma, S., et al. (2019) Molecular Mech-anism Involved in Cyclophosphamide-Induced Cardiotoxicity: Old Drug with a New Vision. Life Sciences, 218, 112-131. https://doi.org/10.1016/j.lfs.2018.12.018
|
[29]
|
Refaie, M.M., El-Hussieny, M., Bayoumi, A.M., et al. (2022) Simvastatin Cardioprotection in Cyclophosphamide-Induced Toxicity via the Modulation of Inflam-masome/Caspase1/Interleukin1beta Pathway. Human & Experimental Toxicology, 41, Article ID: 774837616. https://doi.org/10.1177/09603271221111440
|
[30]
|
Hu, Y., Sun, B., Zhao, B., et al. (2018) Cisplatin-Induced Cardi-otoxicity with Midrange Ejection Fraction: A Case Report and Review of the Literature. Medicine (Baltimore), 97, E13807. https://doi.org/10.1097/MD.0000000000013807
|
[31]
|
Chowdhury, S., Sinha, K., Banerjee, S., et al. (2016) Taurine Protects Cisplatin Induced Cardiotoxicity by Modulating Inflammatory and Endoplasmic Reticulum Stress Re-sponses. Biofactors, 42, 647-664.
https://doi.org/10.1002/biof.1301
|
[32]
|
Saleh, D.O., Mansour, D.F. and Mostafa, R.E. (2020) Rosuvastatin and Simvastatin Attenuate Cisplatin-Induced Cardiotoxicity via Disruption of Endoplasmic Reticulum Stress-Mediated Apoptotic Death in Rats: Targeting ER-Chaperone GRP78 and Calpain-1 Pathways. Toxicology Reports, 7, 1178-1186. https://doi.org/10.1016/j.toxrep.2020.08.026
|
[33]
|
Herrmann, J. (2020) Vascular Toxic Effects of Cancer Therapies. Nature Reviews Cardiology, 17, 503-522.
https://doi.org/10.1038/s41569-020-0347-2
|
[34]
|
Herrmann, J. (2020) Adverse Cardiac Effects of Cancer Therapies: Cardiotoxicity and Arrhythmia. Nature Reviews Cardiology, 17, 474-502. https://doi.org/10.1038/s41569-020-0348-1
|
[35]
|
Campia, U., Moslehi, J.J., Amiri-Kordestani, L., et al. (2019) Cardio-Oncology: Vascular and Metabolic Perspectives: A Scientific Statement from the American Heart Association. Circulation, 139, E579-E602.
https://doi.org/10.1161/CIR.0000000000000641
|
[36]
|
Muhammad, R.N., Sallam, N. and El-Abhar, H.S. (2020) Activated ROCK/Akt/ENOS and ET-1/ERK Pathways in 5-Fluorouracil-Induced Cardiotoxicity: Modulation by Simvas-tatin. Scientific Reports, 10, Article No. 14693.
https://doi.org/10.1038/s41598-020-71531-8
|
[37]
|
Madeddu, C., Deidda, M., Piras, A., et al. (2016) Pathophysiol-ogy of Cardiotoxicity Induced by Nonanthracycline Chemotherapy. Journal of Cardiovascular Medicine (Hagerstown), 17, S12-S18.
https://doi.org/10.2459/JCM.0000000000000376
|
[38]
|
Wu, P., Oren, O., Gertz, M.A., et al. (2020) Proteasome In-hibitor-Related Cardiotoxicity: Mechanisms, Diagnosis, and Management. Current Oncology Reports, 22, Article No. 66. https://doi.org/10.1007/s11912-020-00931-w
|
[39]
|
Drobni, Z.D., Alvi, R.M., Taron, J., et al. (2020) Association between Immune Checkpoint Inhibitors with Cardiovascular Events and Atherosclerotic Plaque. Circulation, 142, 2299-2311.
https://doi.org/10.1161/CIRCULATIONAHA.120.049981
|
[40]
|
Han, X., Zhou, Y. and Liu, W. (2017) Precision Cardio-Oncology: Understanding the Cardiotoxicity of Cancer Therapy. NPJ Precision Oncology, 1, Article No. 31. https://doi.org/10.1038/s41698-017-0034-x
|
[41]
|
Ewer, M.S., Suter, T.M., Lenihan, D.J., et al. (2014) Cardiovas-cular Events among 1090 Cancer Patients Treated with Sunitinib, Interferon, or Placebo: A Comprehensive Adjudicated Database Analysis Demonstrating Clinically Meaningful Reversibility of Cardiac Events. European Journal of Cancer, 50, 2162-2170.
https://doi.org/10.1016/j.ejca.2014.05.013
|
[42]
|
Cole, D.C. and Frishman, W.H. (2018) Cardiovascular Complica-tions of Proteasome Inhibitors Used in Multiple Myeloma. Cardiology in Review, 26, 122-129. https://doi.org/10.1097/CRD.0000000000000183
|
[43]
|
Zhao, Y., Xue, T., Yang, X., et al. (2010) Autophagy Plays an Important Role in Sunitinib-Mediated Cell Death in H9c2 Cardiac Muscle Cells. Toxicology and Applied Pharmacol-ogy, 248, 20-27.
https://doi.org/10.1016/j.taap.2010.07.007
|
[44]
|
Cohen, J.D., Babiarz, J.E., Abrams, R.M., et al. (2011) Use of Human Stem Cell Derived Cardiomyocytes to Examine Sunitinib Mediated Cardiotoxicity and Electrophysiological Al-terations. Toxicology and Applied Pharmacology, 257, 74-83. https://doi.org/10.1016/j.taap.2011.08.020
|
[45]
|
Zheng, Y., Huang, S., Xie, B., et al. (2023) Cardiovascular Toxicity of Proteasome Inhibitors in Multiple Myeloma Therapy. Current Problems in Cardiology, 48, Article ID: 101536. https://doi.org/10.1016/j.cpcardiol.2022.101536
|
[46]
|
Lyon, A.R., Yousaf, N., Battisti, N., et al. (2018) Immune Checkpoint Inhibitors and Cardiovascular Toxicity. The Lancet Oncology, 19, E447-E458. https://doi.org/10.1016/S1470-2045(18)30457-1
|
[47]
|
Nardi, A.I., Itzhaki, B.Z.O. and Kornowski, R. (2022) The Potential Cardiotoxicity of Immune Checkpoint Inhibitors. Journal of Clinical Medicine, 11, Article No. 865. https://doi.org/10.3390/jcm11030865
|
[48]
|
Hu, J.R., Florido, R., Lipson, E.J., et al. (2019) Cardiovascular Toxici-ties Associated with Immune Checkpoint Inhibitors. Cardiovascular Research, 115, 854-868. https://doi.org/10.1093/cvr/cvz026
|
[49]
|
Minegishi, S., Horita, N., Ishigami, T., et al. (2023) Cardiotoxicity Associ-ated with Immune Checkpoint Inhibitors. Cancers (Basel), 15, Article No. 5487. https://doi.org/10.3390/cancers15225487
|